Clinical Analysis for Post-Treatment Tissue Atrophy of Hemangiomas and Vascular Malformations: 353 cases

doi:10.3969/j.issn.1673-0364.2020.03.004

Abstract

Abstract:

Objective To investigate the relative factors of local tissue atrophy after treatment of hemangioma (HA) and vascular malformation (VM).

Methods

A retrospective analysis was performed on 353 HA or VM patients from January 2010 to December 2012, and statistical analysis was performed on the factors that may be related to the occurrence of local tissue atrophy.

Results Among the 353 cases, 17 cases suffered tissue atrophy. The overall incidence of tissue atrophy was 4.82%. Single factor analysis of variance showed that isotope therapy, ulceration and sclerotherapy only were the factors affecting local tissue atrophy (P<0.05). Gender, age, type, cryotherapy had no obvious relation with the occurrence of tissue atrophy (P>0.05). Followed multivariate logistic regression analysis showed that isotope therapy and ulceration were independent risk factors for tissue atrophy, and sclerotherapy only was a protected factor.

Conclusion Sclerotherapy is recommended as the main treatment mean of HA and VM, because of its satisfactory effects on the treatment and low incidence of tissue depression. Nonetheless, the principle of injection should be strictly observed. Isotopic therapy and ulceration are two independent risk factors for tissue atrophy.

Key words: Sclerotherapy, Hemangiomas, Vascular malformations, Ulceration, Isotope therapy, Tissue atrophy

CLC Number:

R732.2

Zhen MENG, Renrong LV, Li LIN, Ran HUO. Clinical Analysis for Post-Treatment Tissue Atrophy of Hemangiomas and Vascular Malformations: 353 cases[J]. Journal of Tissue Engineering and Reconstructive Surgery, 2020, 16(3): 189-192.

Figures/Tables 4

Fig. 1

Fig. 2

Table 1

Table 2

References 18

[1]	Garzon M . Hemangiomas: update on classification, clinical presentation, and associated anomalies[J]. Cutis, 2000,66(5):325-328.
[2]	Zvulunov A, Metzker A . Hemangiomas and vascular malformations: unapproved treatments[J]. Clin Dermatol, 2002,20(6):660-667.
[3]	Yang H, Hu DL, Shu Q , et al. Efficacy and adverse effects of oral propranolol in infantile hemangioma: a meta-analysis of comparative studies[J]. World J Pediatr, 2019,15(6):546-558.
[4]	Huang Z, Zhang N, Cai H , et al. Efficacy of propranolol and pingyangmycin, respectively, combined with pulsed dye laser on children with hemangioma[J]. Exp Ther Med, 2020,19(2):1197-1202.
[5]	Masiha H, Nikpour HA, Hasani ME , et al. The synergistic effect of bleomycin, triamcinolone and epinephrine in treatment of hemangioma and arteriovenous malformations[J]. World J Plast Surg, 2012,1(2):83-90.
[6]	Bernabeu-Wittel J, Pereyra-Rodríguez JJ, Mantrana-Bermejo ME , et al. Propranolol for the treatment of severe hemangiomas of infancy: results from a series of 28 patients[J]. Actas Dermosifiliogr, 2011,102(7):510-516.
[7]	林晓曦 . 血管瘤和血管畸形的研究进展、经验和展望[J]. 中华整形外科杂志, 2011,27(3):161-165.
[8]	张世仁, 仇雅璟, 蔡宜佐 , 等. 婴幼儿血管瘤瘤体内注射药物治疗研究进展[J]. 中华整形外科杂志, 2019,39(2):201-204.
[9]	方川, 薛伶俐, 李雅冬 . 聚桂醇与平阳霉素对血管瘤及静脉畸形疗效及安全性的Meta分析[J]. 解放军医学杂志, 2019,44(9):757-762.
[10]	Ademi Abdyli R, Abdyli Y, Perjuci F , et al. Sclerotherapy of intraoral superficial hemangioma[J]. Case Rep Dent, 2016,2016:4320102.
[11]	陈宣锋, 张世仁, 常雷 , 等. 婴幼儿血管瘤消退后远期纤维脂肪残余及皮肤质地改变[J]. 实用医院临床杂志, 2019,16(6):20-23.
[12]	张莉, 王君, 张成书 , 等. 平阳霉素和曲安奈德治疗血管瘤临床对比研究[J]. 蚌埠医学院学报, 2007,32(3):281-283.
[13]	韩丽娟, 王向东, 冯昭 , 等. 糖皮质激素注射治疗瘢痕致组织凹陷的规避方法及体会[J]. 中国美容医学, 2013,22(17):1791-1792.
[14]	Jang WS, Park J, Yoo KH , et al. Branch-shaped cutaneous hypopigmentation and atrophy after intralesional triamcinolone injection[J]. Ann Dermatol, 2011,23(1):111-114.
[15]	Park J, Chang M . Eyelid fat atrophy and depigmentation after an intralesional injection of triamcinolone acetonide to treat chalazion[J]. J Craniofac Surg, 2017,28(3):e198-e199.
[16]	黄海金, 何晓东, 刘海金 , 等. 应慎用的方法:婴幼儿型血管瘤的同位素敷贴治疗[J]. 中国小儿血液与肿瘤杂志, 2015,20(6):286-288.
[17]	陆海燕 . 90Sr-90Y皮肤敷贴器治疗婴幼儿单纯性毛细血管瘤和成人瘢痕疙瘩疗效分析[J]. 现代医药卫生, 2015,31(13):1997-1998.
[18]	侯媛媛 . 同位素放射治疗血管瘤130例疗效观察[J]. 中国实用医药, 2013,8(22):119-120.

		凹陷(例) cases with atrophy (n)	未凹陷(例) cases without atrophy (n)	凹陷率% atrophy rate (%)
性别	男 M	5	133	3.62
gender	女 F	12	203	5.58
年龄	≤1Y	11	202	5.16
age	>1Y	6	134	4.29
类型	血管瘤 HA	11	210	4.98
type	脉管畸形VM	6	126	4.55
同位素治疗	Yes	6	15	28.57
isotope therapy	No	11	321	3.31
冷冻治疗	Yes	2	15	11.76
cryotherapy	No	15	321	4.46
破溃	Yes	5	16	23.81
ulceration	No	12	320	3.61
单纯注射治疗	Yes	5	231	2.12
sclerotherapy only	No	12	105	10.26

	β	S.E,	Wals	df	Sig.(P)	Exp (β) (OR)	EXP(β)95%C.I
	β	S.E,	Wals	df	Sig.(P)	Exp (β) (OR)	lower limit	upper limit
同位素治疗(isotope therapy)	2.474	0.659	14.075	1	0.000	11.868	3.259	43.216
破溃(ulceration)	1.770	0.680	6.765	1	0.009	5.870	1.547	22.275
单纯注射治疗(sclerotherapy only)	-1.810	0.598	9.143	1	0.002	0.164	0.051	0.529
常量(constant)	-2.737	0.377	52.599	1	0.000	0.065